In the next two days, while Yang Chen inspected the work of the company in the United States, he also took time to participate in the board of directors of all shareholders of Shire Company initiated by Old Jack.

For Kampo medicine, he can learn from island countries, but there is obviously no way to deal with Western medicine. He must rely on pharmaceutical companies from European and American countries such as the United States.

Shire is his first step into Western medicine. As long as the board of directors approves it, Shire's strength can help him build a modern and first-class pharmaceutical production factory in Xiangjiang.

Affected by the overall environment of the pharmaceutical industry, Shire shareholders still have a certain interest in entering the Asian market.

There is nothing you can do if you are not interested. The proposal was put forward by Yang Chen, the third largest shareholder of the company, and Old Jack, the major shareholder and chairman, agreed.

Therefore, none of the other directors on the board of directors expressed opposition to Yang Chen's proposal.

Even Shire's second largest shareholder did not express any objection to the company's plan to open a branch in Asia.

Thanks to Yang Chen's money offensive, with the establishment of the Asian branch, the Shire head office only needs to hire people, issue prescriptions and other free tasks. All other expenses are covered by Yang Chen, who is not short of money.

Responsible.

Shire's head office occupies 40% of the shares of the Asian branch without paying a penny. This kind of advantage cannot be taken advantage of.

Of course, this is only one of the reasons.

What really makes everyone accept that Yang Chen controls the branch and enjoys the final pricing power is that most shareholders do not pay attention to the current Asian market.

Although Asia has a great advantage in terms of population, it is still in the initial stage of development. Many developing countries have never really paid attention to drug patents.

It is simply not feasible to sell high-priced medicines. The only option is small profits but quick turnover.

Except for Asian countries with rapid economic development such as island countries and South Korea, most Asian countries have not done a good job in protecting pharmaceutical patents even in the 21st century.

The general direction of Shire's majority shareholders is to focus on the domestic market of the United States, as well as developed countries with sound systems such as Europe.

If Yang Chen wants to obtain the final pricing power in the market of a developed country, there is no way he can do it. He doesn't even have to think about it. Not to mention that the shareholders won't agree, I'm afraid even Old Jack won't agree either.

"Boss, Manager Shen is here."

"boss"

Although this was not the first time for Shen Xu to meet Yang Chen, this was the first time for him to meet in private like this. Especially two days ago, Orange Technology was successfully listed in the United States, which made Yang Chen's net worth skyrocket.

Facing this new richest man in China, the big boss who rewarded him with a job, Shen Xu didn't dare to be disrespectful in the slightest.

"Sit down, don't stand."

"Thank you boss"

Regardless of Shen Xu's reserved look, Huo Jianheng took out a contract from his briefcase and handed it to Yang Chen.

"Boss, I persuaded several small shareholders of Shire Company to buy out the 6% of Shire Company shares they held.

From now on, we hold 24% of Shire's shares.

This is an equity transfer contract. The shares we hold have exceeded Mr. Nice (the former second shareholder of Shire). If we add the shares held by Chairman Jack, the shares of Shire held by the two of us are

Already more than half.

Next, I will raise funds to expand shares. I think Mr. Jack will not reduce his shareholdings. At that time, as long as we continue to absorb Shire's shares and keep the shares held from falling below 20%, we can ensure that Asia will continue to grow in the future. The branch was successfully completed.”

Yang Chen took the equity transfer letter handed over by Huo Jianhuang, glanced at it, and handed it to Shen Xu, who was sitting at attention, and said: "Manager Shen, I think Manager Huo has already told you about the matter on the way. Make it clear.

This time I transferred you from Orange Technology to take charge of this matter. I hope you can handle the matter well. Next, I will notify Shire Company and you will have full authority to handle the relevant matters on my behalf.

In addition to ensuring that the shares we hold will not decline during the financing process, we also need to urge Shire head office to speed up the process."

"If there is an opportunity, I hope you can persuade Shire shareholders for me to move Shire's pharmaceutical factories to Asia."

"Of course, this matter cannot be done urgently and there will certainly be no results in a short time. However, as labor costs in the United States continue to rise, many American companies have begun to move their factories out of the United States.

The U.S. government also intends to outsource these factories, so we can slowly wait for the opportunity. As long as the opportunity comes, you must seize it. If it doesn't work, just call me and let me know."

Seeing Yang Chen's serious face, Shen Xu obviously took this matter very seriously, and he became interested.

Without waiting for Shen Xu to speak, Yang Chen continued: "By the way, after the branch in Asia is established, you need to visit more American medical universities to help the company recruit some top medical talents. We can't just produce , instead of researching new drugs..."

Yang Chen has always known a truth.

That is, what belongs to others will always belong to others, and some things only belong to you if you master them.

This world has never lacked cases of small people counterattacking. By the same token, branches are not necessarily worse than the head office.

As long as he is willing to invest, it is not a fantasy to be on an equal footing with Shire Corporation in the future with the entire Asian market.

Shire is not a leading company in the U.S. pharmaceutical industry. It is only among the pharmaceutical companies and ranks relatively high. There are many excellent pharmaceutical companies in the U.S., and Shire will face very strong competitive pressure in the future.

But Yang Chen's side is different. The entire Asian market is still being cultivated. Compared with the American market, the competitive pressure will be much smaller.

One goes off the other, and he doesn't feel any pressure at all when it comes to the branch's counterattack.

Furthermore, he also holds stocks of other American pharmaceutical companies. As long as they work well, he can become the general agent of American pharmaceutical companies in Asia.

Of course, a small agent will definitely not be able to satisfy his appetite, even if this agent controls the drug pricing power and production chain.

His goal is to build the world's top pharmaceutical research institute to compete with the world's top pharmaceutical companies in the future.

In other words, he hopes that his future pharmaceutical company can make contributions and benefit all mankind.

Ahem, okay, those things are still too far away.

It cannot be accomplished overnight.

Now, let’s be practical. Set a small goal first, build a pharmaceutical factory, and get the title of general agent.
Chapter completed!